Year: 2017
Type: review
Abstract: PURPOSE OF REVIEW: Leber hereditary optic neuropathy (LHON) is the most common primary mitochondrial DNA (mtDNA) genetic disorder in the population. We address the clinical evolution of the disease, the secondary etiological factors that could contribute to visual loss, and the challenging task of developing effective treatments. RECENT FINDINGS: LHON is characterized by a preclinical phase that reflects retinal ganglion cell (RGC) dysfunction before rapid visual deterioration ensues. Children can present atypically with slowly progressive visual loss or an insidious/subclinical onset that frequently results in considerable diagnostic delays. The LHON mtDNA mutation is not sufficient on its own to precipitate RGC loss and the current body of evidence supports a role for smoking and estrogen levels influencing disease conversion. Clinical trials are currently investigating the efficacy of adeno-associated viral vectors-based gene therapy approaches for patients carrying the m.11778G>A mutation. Mitochondrial replacement therapy is being developed as a reproductive option to prevent the maternal transmission of pathogenic mtDNA mutations. SUMMARY: LHON is phenotypically more heterogeneous than previously considered and a complex interplay of genetic, environmental and hormonal factors modulates the risk of a LHON carrier losing vision. Advances in disease modelling, drug screening and genetic engineering offer promising avenues for therapeutic breakthroughs in LHON.
Source: Current Opinion in Ophthalmology
Authors: Neringa Jurkute, Patrick Yu-Wai-Man
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Keywords: Leber's hereditary optic neuropathy, mitochondrial DNA mutations, m.11778G>A mutation, retinal ganglion cell death, vision loss, smoking, estrogen, disease transformation, adeno-associated virus vectors, gene therapy, mitochondrial replacement therapy, mother-to-child transmission, preclinical disease, disease modeling, drug screening
Open Access status: green
Estimated APC paid: $3,607
Award: G1672547395
OpenAlex ID: W2724870532
